UroGen Pharma Ltd - Asset Resilience Ratio
UroGen Pharma Ltd (URGN) has an Asset Resilience Ratio of 11.95% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how UroGen Pharma Ltd's Asset Resilience Ratio has changed over time. Check UroGen Pharma Ltd (URGN) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down UroGen Pharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of UroGen Pharma Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $30.31 Million | 11.95% |
| Total Liquid Assets | $30.31 Million | 11.95% |
Asset Resilience Insights
- Moderate Liquidity: UroGen Pharma Ltd has 11.95% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
UroGen Pharma Ltd Industry Peers by Asset Resilience Ratio
Compare UroGen Pharma Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for UroGen Pharma Ltd (2015–2025)
The table below shows the annual Asset Resilience Ratio data for UroGen Pharma Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.84% | $9.71 Million | $200.46 Million | -17.80pp |
| 2024-12-31 | 22.64% | $64.70 Million | $285.71 Million | -0.89pp |
| 2023-12-31 | 23.54% | $41.97 Million | $178.31 Million | -9.32pp |
| 2022-12-31 | 32.85% | $44.56 Million | $135.62 Million | -4.54pp |
| 2021-12-31 | 37.39% | $44.78 Million | $119.75 Million | -2.89pp |
| 2020-12-31 | 40.29% | $49.15 Million | $122.00 Million | -7.83pp |
| 2019-12-31 | 48.12% | $97.39 Million | $202.39 Million | +0.47pp |
| 2017-12-31 | 47.65% | $36.00 Million | $75.55 Million | +47.24pp |
| 2016-12-31 | 0.41% | $95.00K | $23.06 Million | +0.30pp |
| 2015-12-31 | 0.11% | $21.00K | $19.39 Million | -- |
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more